Conclusions: Use of liraglutide was associated with significantly lower risk of MACE and death in patients with type 2 diabetes and high cardiovascular risk using basal insulin.
cardiovascular outcomes trials of antihyperglycaemic medications have been conducted.
The cardiovascular safety of basal insulin glargine 100 units/mL (glargine U100) and insulin degludec (degludec) was established by the open-label ORIGIN and double-blind DEVOTE randomized trials, respectively, both of which included patients at high risk of cardiovascular events. 3, 4 In 2011, the final results from the Outcome Reduction significantly reduced the relative risk of MACE by 13%, the risk of cardiovascular death by 22% and the risk of all-cause mortality by 15% versus placebo. 5 Liraglutide also reduced the proportion of patients undergoing treatment intensification with antihyperglycaemic medications, including insulin, and the risks of severe hypoglycaemia and confirmed hypoglycaemia versus placebo. 5 Based on the results of the LEADER trial, liraglutide was recommended as a treatment option in the treatment guidelines for patients with type 2 diabetes and established cardiovascular disease. 6, 7 Consensus guidelines support the combination of a basal insulin and a GLP-1RA as a treatment option for individuals with type 2 diabetes. [7] [8] [9] For example, triple therapy, which can include the combination of metformin and a GLP-1RA with basal insulin (or oral antihyperglycaemic drugs), is recommended if a patient with type 2 diabetes has not achieved his/her HbA1c target after 3 months of dual therapy. [7] [8] [9] Combining injectable therapies consisting of basal insulin and a GLP-1RA, usually with metformin (with or without another noninsulin agent), should also be considered if the patient has not achieved the HbA1c target after 3 months of triple therapy using another regimen, 8 or when blood glucose is ≥16.7 mmol/L, HbA1c ≥ 10% (≥86 mmol/mol) or the patient has symptoms of hyperglycaemia. 7, 8 Clinical studies evaluating insulin and GLP-1RA combination therapy (both fixed and free combinations) for type 2 diabetes have shown beneficial effects of this regimen on glycaemic control and body weight, or weight neutrality, versus comparators. [10] [11] [12] [13] Some insulin/GLP-1RA combinations also allow for reductions in existing insulin doses. [10] [11] [12] [13] Furthermore, adding a GLP-1RA to insulin therapy has been shown to decrease the risk of hypoglycaemia, even with improved HbA1c levels. 9, [13] [14] [15] The aim of this post hoc analysis was to compare the associations between concomitant liraglutide use versus no liraglutide use and the occurrence of MACE and all-cause mortality among patients receiving basal insulin (either degludec or glargine U100) in DEVOTE.
This analysis was also repeated for the individual MACE components, serious adverse events and severe hypoglycaemic episodes.
| MATERIALS AND METHODS

| Trial design
The design of DEVOTE (ClinicalTrials.gov: NCT01959529) has been described previously. 4, 16 The trial was conducted in accordance with 4 Patients were eligible for inclusion if they were aged ≥50 years and had at least one co-existing cardiovascular condition or chronic kidney disease, or if they were aged ≥60 years and had at least one cardiovascular risk factor. 4 From November 2013, 7637 participants were randomized 1:1 to receive degludec or glargine U100 in a blinded fashion, both in identical 10 mL vials containing 100 U/mL, added to standard care and administered once daily between dinner and bedtime. 4 Randomized participants could continue their pretrial antihyperglycaemic therapy, except for basal and premix insulins, which were discontinued at randomization. 4 The primary composite outcome was the time from randomization to the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (MACE). DEVOTE was designed to continue until at least 633 MACE (confirmed by a central, blinded Event Adjudication Committee) had occurred. 4 Overall, the median observation time was 1.99 (0-2.75) years.
Secondary outcomes included the time from randomization to death from any cause (all-cause mortality), serious adverse events and adjudicated severe hypoglycaemia. 4 Severe hypoglycaemia was defined, in accordance with criteria recommended by the American Diabetes Association, 19 as an episode requiring the assistance of another person to actively administer carbohydrate or glucagon or to take other corrective actions. (Table S1 , Supporting Information).
Sensitivity analyses were also conducted to account for the possible impact of concomitant sodium-glucose co-transporter-2 (SGLT-2) inhibitor use on outcomes. For these analyses, patients who used SGLT-2 inhibitors at baseline were excluded from the concomitant liraglutide use group and included in the no concomitant liraglutide use group.
3 | RESULTS
| Exposure to liraglutide during the trial
Among all randomized participants at baseline, only a limited number of patients used a GLP-1RA (n = 604; 7.9%). Of these patients, (Figure 1 ). Importantly, all of these results from these analyses were observed while the overall effect of degludec versus glargine U100 seen in the primary analysis was preserved (data not shown).
Among the 436 patients who were receiving liraglutide at base- 
| Sensitivity analyses
HRs from the sensitivity analyses adjusted for additional baseline cov- Abbreviations: CI, confidence interval; HR, hazard ratio; glargine U100, insulin glargine 100 units/mL; MACE, major adverse cardiovascular events; N, number of events; Rate, events per 100 patient-years of observation. Full analysis set (all randomized patients). HRs presented are for time to the first confirmed event (in days), comparing concomitant liraglutide use with no concomitant liraglutide use. HRs are based on a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial, without interaction. Thus, the analyses are adjusted for patients initiating, interrupting or discontinuing liraglutide treatment during the trial. For one patient who experienced an event occurring on the same day as liraglutide initiation, half a day was added to the day of the event. 
| Patient characteristics
Overall, the group who received liraglutide at any time during the trial (n = 623) and the group who never used liraglutide during the trial (n = 7014) were similar at screening or baseline. At screening or Abbreviations: CI, confidence interval; HR, hazard ratio; glargine U100, insulin glargine 100 units/mL; N, number of events; Rate, events per 100 patientyears of observation. Full analysis set (all randomized patients). HRs presented are for time to the first confirmed event (in days), comparing concomitant liraglutide use with no concomitant liraglutide use. HRs are based on a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial, without interaction. Thus, the analyses are adjusted for patients initiating, interrupting or discontinuing liraglutide treatment during the trial. For one patient who experienced an event occurring on the same day as liraglutide initiation, half a day was added to the day of the event.
FIGURE 2 Adjusted analyses of major clinical outcomes by time-varying liraglutide use. Full analysis set (all randomized patients). HRs presented are for time to the first confirmed event (in days), comparing concomitant liraglutide use with no concomitant liraglutide use. HRs are based on a Cox regression model adjusted for treatment and time-varying liraglutide use at any time during the trial alongside additional baseline factors and covariates, including age, sex, smoking status, race, diabetes duration, cardiovascular risk group, insulin treatment, HbA1c, BMI, systolic blood pressure, LDL cholesterol, HDL cholesterol, hepatic impairment category and renal impairment category, all without interaction. Thus, the analyses are adjusted for patients initiating, interrupting or discontinuing liraglutide treatment during the trial. For one patient who experienced an event occurring on the same day as liraglutide initiation, half a day was added to the day of the event. CI, confidence interval; HR, hazard ratio; MACE, major adverse cardiovascular events; N, number of events; Rate, events per 100 patient-years of observation, BMI, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein baseline, the group who received liraglutide at any time during the trial had numerically higher mean body weight and BMI, but numerically lower mean HbA1c, systolic blood pressure, total cholesterol and LDL cholesterol than the group who never received liraglutide during the trial. Additional patient characteristics and antihyperglycaemic and cardiovascular medication use for these two groups at screening or baseline are shown in Table S1 , Supporting Information.
| Insulin use
After 24 months of randomized treatment, mean basal insulin doses were the same for patients who did or did not receive liraglutide at any time (0.7 ± 0.4 units/kg) ( Figure S3 and Table S2 , Supporting Information). Mean bolus insulin doses used after 24 months of randomized treatment were slightly lower in the group who received liraglutide at any time (0.5 ± 0.5 units/kg) than in the group who never used liraglutide (0.6 ± 0.5 units/kg) ( Figure S4 and Table S2 , Supporting Information).
| DISCUSSION
These post hoc analyses of data from DEVOTE examined if the use of liraglutide was associated with differences in the occurrence of MACE and all-cause mortality in users of basal insulin (degludec or glargine U100) with type 2 diabetes and high cardiovascular risk. Pooled data from patients receiving degludec or glargine U100 showed that concomitant liraglutide use versus no concomitant liraglutide use was associated with a 38% lower HR for MACE and a 50% lower HR for allcause mortality (both statistically significant), suggesting that the combination of liraglutide and basal insulin may be associated with a cardiovascular benefit. This is in line with the main finding from the LEADER trial, 5 where liraglutide significantly reduced the risks of MACE, cardiovascular death and all-cause mortality versus placebo in patients with type 2 diabetes at high cardiovascular risk. Similarly, in a post hoc analysis of basal insulin-treated patients in LEADER, treatment with liraglutide versus placebo resulted in a cardiovascular risk reduction similar to the results from the main trial and was also associated with a 50% reduction in severe hypoglycaemia. 20 In addition, in the present study a range of sensitivity analyses were conducted for these outcomes, including adjusting for additional baseline covariates and extending the time window for liraglutide use. Results from these sensitivity analyses were consistent with the main findings, suggesting that they are robust.
There are a number of observations from the LEADER trial that provide supporting context for our analysis. Observations from our post hoc analysis are supported by analyses of LEADER subgroups receiving insulin with or without an oral antihyperglycaemic agent (OHA) at baseline. 5 In both of these LEADER subgroups, fewer patients experienced MACE with liraglutide versus placebo, although the differences did not reach statistical significance [HR for insulin with OHA at baseline 0.89 (0.74; 1.06) 95%CI ; HR for insulin without OHA at baseline 0.86 (0.63; 1.17) 95% CI ]. 5 However, the LEADER trial was not powered to detect significant differences in MACE in the post hoc analysis because of the smaller number of patients included in these subgroups versus the overall LEADER population. 5 Additionally, the observation that liraglutide reduced treatment intensification with antihyperglycaemic medications during the LEADER trial, including insulin, 5 complicates the interpretation of these data.
Our analysis only included those patients treated with liraglutide in DEVOTE and not all GLP-1RAs. This was primarily because of the small proportion of patients who used a GLP-1RA that was not liraglutide, which would not have allowed for a meaningful comparison.
Furthermore, the cardiovascular benefit of some other GLP-1RAs had not been shown. On this basis, only those patients treated with liraglutide were investigated. In the United States, liraglutide is indicated to reduce the risk of MACE in adults with type 2 diabetes and established cardiovascular disease. 21 In addition, treatment guidelines were updated to mention liraglutide as the GLP-1RA to be used in patients with type 2 diabetes and established cardiovascular disease. [6] [7] [8] The mechanisms underlying the reduction in MACE with liraglutide have not been fully established, but an antiatherogenic effect may be involved. 22 Reductions in body weight and visceral fat, Lastly, potential between-group differences were noted in the baseline characteristics of patients who did or did not use liraglutide during the trial at any time. These differences may be because of socioeconomic factors and treatment goals for individual patients, which were not possible to account for in this analysis. However, the sensitivity analyses that adjusted for a range of additional covariates were consistent with those obtained in the main analyses, suggesting that these factors did not impact the prevalence of these outcomes. Nevertheless, residual confounding cannot be excluded.
This study also had a number of strengths. This analysis was based on data from a large, double-blind, cardiovascular outcomes trial, with independent adjudication of cardiovascular and severe hypoglycaemic events. In addition, the sensitivity analyses that 
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